Senior Vice President &
Head of Global Business Development and Alliance Management
Philippe Lopes-Fernandes is Senior Vice President & Head of Global Business Development and Alliance Management for the biopharmaceutical business of Merck KGaA, Darmstadt, Germany.
Searching for innovative opportunities, Philippe is responsible for securing access to external innovation through investing in alliances, in-licensing opportunities and potential acquisitions.
Philippe, and his team provide end-to-end transaction support to ensure execution of these high quality global deals at all stages of project development.
He has directly negotiated key deals for Merck KGaA, Darmstadt, Germany, including the in-licensing of Erbitux, the acquisition of Serono, the sale of the company's generic business to Mylan, and most recently the alliance with Pfizer on Avelumab.1
Philippe started his professional career at Merck KGaA, Darmstadt, Germany, joining the company as product manager in 1993. He held various positions within the organization, mainly in Business Development, and Alliance Management, but also in Merger & Acquisitions as head of this department.
Philippe holds a graduate degree in Business Administartion from Institut Superieur de Gestion in Paris, France.
1Avelumab is the proposed International Non-proprietary Name (INN) for the anti-PD-L1 monoclonal antibody (previously known as MSB 0010718C)